2015年美國心髒學會(AHA)科學年會公布的一項研究表明，與廣泛應用的Ⅲ類抗心律失常藥物伊布利特相比，多通道阻滯劑維納卡蘭(vernakalant)可更快更好地恢複近期發作的房顫急診患者竇性心律。

維納卡蘭是一種速效抗心律失常藥物。研究者們納入100例近期發作的房顫急診患者。接受維納卡蘭和伊布利特治療的患者分別為49例和51例，在這些患者中對比兩種藥物的療效。

結果顯示，維納卡蘭組恢複竇性心律的平均時間為10分鍾，而伊布利特組則為26分鍾；維納卡蘭組在90分鍾內逆轉成功率明顯較高，達69%，而伊布利特組的這一比例為43%。兩組均未發生嚴重治療相關的並發症。

New drug restores irregular heart rhythm more often and much faster

By AMERICAN HEART ASSOCIATION NEWS

The multi-channel blocker vernakalant restored sinus rhythm more often and much faster than the widely used class III drug ibutilide in patients presenting to the emergency room with recent-onset atrial fibrillation (quivering or irregular heartbeat), according to a study presented at the American Heart Association’s Scientific Sessions 2015.

Vernakalant, like ibutilide, is a rapid-acting antiarrhythmic drug. Researchers compared the drugs’ effects by studying 100 patients with recent onset atrial fibrillation in a hospital emergency room.

Forty-nine patients received up to two infusions of vernakalant; 51 received intravenous ibutilide.

Researchers found:

• It took an average of 10 minutes to normalize heart rhythms with vernakalant, compared to 26 minutes with ibutilide.

• Conversion success within 90 minutes was notably higher in the vernakalant group (69 percent) compared to those who received ibutilide (43 percent).

No serious treatment-related complications occurred in either group.